HDAX Therapeutics

HDAX Therapeutics is a pioneering biotech company focused on developing innovative small molecules to address inadequacies in current treatments for neurology and cardiometabolic diseases. The company leverages proprietary technology to unlock novel binding mechanisms to key biological molecules, improving targeting and ultimately enhancing patient outcomes. HDAX Therapeutics was founded by Professor Patrick Gunning, a serial entrepreneur with a successful track record in the biotech industry, including ventures like Dunad, Dalriada Drug Discovery, and Janpix. The company operates in the pharmaceutical and biotechnology market, primarily serving patients with unmet medical needs. HDAX Therapeutics' business model revolves around the research and development of proprietary drugs, which are then licensed or sold to pharmaceutical companies, generating revenue through licensing fees, milestone payments, and royalties. The company's initial focus is on HDAC6, a validated target for neurology and cardiometabolic diseases, with the aim of delivering meaningful medicines that significantly improve patient outcomes.

Keywords: HDAC6, small molecules, neurology, cardiometabolic, biotechnology, proprietary technology, drug development, patient outcomes, translational science, innovative treatments.